| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
67,011,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vera Therapeutics is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Co.'s primary product candidate, atacicept, a self-administered fusion protein that blocks both blisibimod and APRIL, is being evaluated for the treatment of immunoglobulin A nephropathy in a global, randomized, double-blind, placebo-controlled clinical trial. Co. has obtained worldwide, exclusive development and commercial rights from Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., for MAU868, a potentially monoclonal antibody to treat BK viremia infections.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
5,882 |
5,882 |
255,882 |
417,172 |
| Total Buy Value |
$249,985 |
$249,985 |
$5,527,296 |
$10,527,286 |
| Total People Bought |
1 |
1 |
1 |
2 |
| Total Buy Transactions |
1 |
1 |
3 |
4 |
| Total Shares Sold |
35,000 |
35,000 |
72,188 |
2,362,317 |
| Total Sell Value |
$1,336,642 |
$1,336,642 |
$2,614,091 |
$72,584,330 |
| Total People Sold |
2 |
2 |
3 |
7 |
| Total Sell Transactions |
3 |
3 |
6 |
30 |
| End Date |
2025-10-09 |
2025-07-08 |
2025-01-07 |
2024-01-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Turner William D. |
Chief Regulatory Officer |
• – – |
2025-12-15 |
4 |
AS |
$50.08 |
$500,767 |
D/D |
(10,000) |
22,500 |
|
- |
|
| Turner William D. |
Chief Regulatory Officer |
• – – |
2025-12-15 |
4 |
OE |
$15.53 |
$155,300 |
D/D |
10,000 |
32,500 |
|
- |
|
| Enright Patrick G |
|
– • – |
2025-12-11 |
4 |
B |
$42.50 |
$249,985 |
D/D |
5,882 |
5,882 |
0.01 |
- |
|
| Turner William D. |
Chief Regulatory Officer |
• – – |
2025-12-03 |
4 |
AS |
$40.00 |
$400,000 |
D/D |
(10,000) |
22,500 |
|
- |
|
| Turner William D. |
Chief Regulatory Officer |
• – – |
2025-12-03 |
4 |
OE |
$15.53 |
$155,300 |
D/D |
10,000 |
32,500 |
|
- |
|
| Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
• – – |
2025-11-13 |
4 |
OE |
$3.94 |
$39,396 |
D/D |
10,000 |
57,839 |
|
- |
|
| Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
• – – |
2025-11-11 |
4 |
S |
$29.06 |
$435,875 |
D/D |
(15,000) |
47,839 |
|
- |
|
| Enright Patrick G |
|
– • – |
2025-06-24 |
4 |
B |
$22.35 |
$907,635 |
I/I |
40,607 |
3,596,593 |
0.01 |
- |
|
| Enright Patrick G |
|
– • – |
2025-06-23 |
4 |
B |
$20.87 |
$4,369,676 |
I/I |
209,393 |
3,569,522 |
0.01 |
- |
|
| Fordyce Marshall |
PRESIDENT AND CEO |
• • – |
2025-02-26 |
4 |
AS |
$27.55 |
$250,882 |
D/D |
(9,075) |
204,665 |
|
- |
|
| Fordyce Marshall |
PRESIDENT AND CEO |
• • – |
2025-02-21 |
4 |
AS |
$27.89 |
$296,032 |
D/D |
(10,613) |
213,740 |
|
- |
|
| Turner William D. |
Chief Development Officer |
• – – |
2025-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
22,500 |
|
- |
|
| Johnson David Lee |
Chief Operating Officer |
• – – |
2025-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
26,900 |
26,900 |
|
- |
|
| Fordyce Marshall |
PRESIDENT AND CEO |
• • – |
2025-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
80,750 |
224,353 |
|
- |
|
| Grant Sean |
CHIEF FINANCIAL OFFICER |
• – – |
2025-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
26,900 |
93,237 |
|
- |
|
| Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
• – – |
2025-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
10,740 |
61,946 |
|
- |
|
| Brenner Robert |
Chief Medical Officer |
• – – |
2025-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
26,900 |
27,474 |
|
- |
|
| Fordyce Marshall |
PRESIDENT AND CEO |
• • – |
2025-01-08 |
4 |
AS |
$41.53 |
$730,535 |
D/D |
(17,500) |
143,603 |
|
- |
|
| Fordyce Marshall |
PRESIDENT AND CEO |
• • – |
2025-01-08 |
4 |
OE |
$2.90 |
$50,694 |
D/D |
17,500 |
145,478 |
|
- |
|
| Fordyce Marshall |
PRESIDENT AND CEO |
• • – |
2024-12-19 |
4 |
OE |
$2.90 |
$167,032 |
D/D |
57,661 |
143,603 |
|
- |
|
| Fordyce Marshall |
PRESIDENT AND CEO |
• • – |
2024-12-18 |
4 |
AS |
$41.33 |
$753,680 |
D/D |
(17,500) |
85,942 |
|
- |
|
| Fordyce Marshall |
PRESIDENT AND CEO |
• • – |
2024-12-18 |
4 |
OE |
$2.90 |
$50,694 |
D/D |
17,500 |
87,817 |
|
- |
|
| Fordyce Marshall |
PRESIDENT AND CEO |
• • – |
2024-12-11 |
4 |
AS |
$46.91 |
$821,523 |
D/D |
(17,500) |
85,942 |
|
- |
|
| Fordyce Marshall |
PRESIDENT AND CEO |
• • – |
2024-12-11 |
4 |
OE |
$2.90 |
$50,694 |
D/D |
17,500 |
86,042 |
|
- |
|
| Fordyce Marshall |
PRESIDENT AND CEO |
• • – |
2024-11-25 |
4 |
AS |
$47.05 |
$929,560 |
D/D |
(19,375) |
85,942 |
|
- |
|
185 Records found
|
|
Page 1 of 8 |
|
|
